Subsequent resection of locally advanced pancreatic carcinoma after chemoradiotherapy

被引:21
作者
Adhoute, X
Smith, D
Vendrely, Y
Rault, A
Cunha, AS
Legoux, JL
Belleannée, G
De Lédinghen, V
Couzigou, P
Masson, B
机构
[1] CHU Bordeaux, Serv Hepatogastroenterol, Hop Haut Leveque, F-33604 Pessac, France
[2] CHU Bordeaux, Med Oncol Serv, F-33604 Pessac, France
[3] CHU Bordeaux, Serv Radiotherapie, Hop St Andre, F-33604 Pessac, France
[4] CHU Bordeaux, Hop Haut Leveque, Anat Pathol Lab, F-33604 Pessac, France
[5] CHU Bordeaux, Serv Chirurg Viscerale, F-33604 Pessac, France
来源
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE | 2006年 / 30卷 / 02期
关键词
D O I
10.1016/S0399-8320(06)73157-8
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives - The aim of this study was to evaluate the possibility of subsequent resection of locally advanced pancreatic adenocarcinoma after chemotherapy and external-beam radiotherapy. Patients and methods - Between January 1996 and January 2001, 33 consecutive patients (18 males and 15 women, mean age 63 years) with locally advanced PA were treated with chemotherapy and concurrent external-beam radiotherapy. Radiotherapy delivered 45-50.4 Gy, in a classical manner (N = 27) or on a split-course (N = 6). Chemotherapy was made of 5FU by continuous infusion for all patients during 5 weeks and cisplatin at the 1(st) and 5(th) weeks (N = 22). Tumor resectability was reassessed at the end of the chemoradiotherapy; surgical resection of tumour was attempted in patients whose tumor demonstrated reduction in size, and supplementary radiotherapy of 10 to 15 Gy was delivered to the others. Results - Thirty-nine percent of patients experienced grade 3 acute toxicity. WHO criteria response to chemoradiotherapy four weeks after the end of treatment were: 4 partial responders (12%), 6 minor responders (18%), 14 stable disease (42%), 9 progression (28%). Ten patients underwent exploratory laparotomy, in one case vascular encasement did not allow for tumor resection, and in another patient, there was peritoneal carcinomatosis. In the 8 remaining patients, surgical (R0) resection was possible. In one patient histological examination showed fibrosis with no residual tumour After a median follow-up period of 40 months, median survival was 16 months (66% and 37% of survival at 1 and 2 years respectively). In operated and non-operated patients, survival rates at 24 months were 73% and 12.5% respectively. At 1 year, 80% of the patients treated with radiochemotherapy developed recurrence, metastatic recurrence in 88%. Initial loparotomy, split course radiotherapy were poor outcome factors whereas chemotherapy appears to be a favorable outcome factor. Conclusion - Subsequent resection of locally advanced pancreatic adenocarcinoma is possible after chemoradiotherapy allowing for a prolonged survival in some patients.
引用
收藏
页码:224 / 230
页数:7
相关论文
共 35 条
[21]   PANCREATIC ADENOCARCINOMA - CT VERSUS MR-IMAGING IN THE EVALUATION OF RESECTABILITY - REPORT OF THE RADIOLOGY DIAGNOSTIC ONCOLOGY GROUP [J].
MEGIBOW, AJ ;
ZHOU, XH ;
ROTTERDAM, H ;
FRANCIS, IR ;
ZERHOUNI, EA ;
BALFE, DM ;
WEINREB, JC ;
AISEN, A ;
KUHLMAN, J ;
HEIKEN, JP ;
GATSONIS, C ;
MCNEIL, BJ .
RADIOLOGY, 1995, 195 (02) :327-332
[22]  
MOERTEL CG, 1981, CANCER, V48, P1705, DOI 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO
[23]  
2-4
[24]   Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer:: a randomised controlled trial [J].
Neoptolemos, JP ;
Dunn, JA ;
Stocken, DD ;
Almond, J ;
Link, K ;
Beger, H ;
Bassi, C ;
Falconi, M ;
Pederzoli, P ;
Dervenis, C ;
Fernandez-Cruz, L ;
Lacaine, F ;
Pap, A ;
Spooner, D ;
Kerr, DJ ;
Friess, H ;
Büchler, MW .
LANCET, 2001, 358 (9293) :1576-1585
[25]   Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: A phase I trial [J].
Safran, H ;
Dipetrillo, T ;
Iannitti, D ;
Quirk, D ;
Akerman, P ;
Cruff, D ;
Cioffi, W ;
Shah, S ;
Ramdin, N ;
Rich, T .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (01) :137-141
[26]   Resected adenocarcinoma of the pancreas - 616 patients: Results, outcomes, and prognostic indicators [J].
Sohn, TA ;
Yeo, CJ ;
Cameron, JL ;
Koniaris, L ;
Kaushal, S ;
Abrams, RA ;
Sauter, PK ;
Coleman, J ;
Hruban, RH ;
Lillemoe, KD .
JOURNAL OF GASTROINTESTINAL SURGERY, 2000, 4 (06) :567-579
[27]   CURRENT TRENDS IN THE DIAGNOSIS AND TREATMENT OF CARCINOMA OF THE PANCREAS [J].
WARREN, KW ;
CHRISTOPHI, C ;
ARMENDARIZ, R ;
BASU, S .
AMERICAN JOURNAL OF SURGERY, 1983, 145 (06) :813-818
[28]  
WARSHAW AL, 1990, ARCH SURG-CHICAGO, V125, P230
[29]   Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas [J].
White, R ;
Lee, C ;
Anscher, M ;
Gottfried, M ;
Wolff, R ;
Keogan, M ;
Pappas, T ;
Hurwitz, H ;
Tyler, D .
ANNALS OF SURGICAL ONCOLOGY, 1999, 6 (01) :38-45
[30]   Staging of pancreatic cancer before and after neoadjuvant chemoradiation [J].
White, RR ;
Paulson, EK ;
Freed, KS ;
Keogan, MT ;
Hurwitz, HI ;
Lee, C ;
Morse, MA ;
Gottfried, MR ;
Baillie, J ;
Branch, MS ;
Jowell, PS ;
McGrath, KM ;
Clary, BM ;
Pappas, TN ;
Tyler, DS .
JOURNAL OF GASTROINTESTINAL SURGERY, 2001, 5 (06) :626-633